Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin Triple Therapy in T2DM
NCT01619059Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2012
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Jun 2012; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01619059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01619059.